Das K, Ghosh A, Hajra A
RSC Adv. 2022; 12(30):19412-19416.
PMID: 35865587
PMC: 9251645.
DOI: 10.1039/d2ra03547b.
Yu K, Hung H
RSC Adv. 2022; 12(1):251-264.
PMID: 35424505
PMC: 8978903.
DOI: 10.1039/d1ra08120a.
Sharma R, Yadav L, Yadav R, Chaudhary S
RSC Adv. 2022; 11(23):14178-14192.
PMID: 35423939
PMC: 8698059.
DOI: 10.1039/d1ra02225c.
Bertron J, Duvernay M, Mitchell S, Smith S, Maeng J, Blobaum A
ACS Chem Neurosci. 2021; 12(24):4524-4534.
PMID: 34855359
PMC: 8823334.
DOI: 10.1021/acschemneuro.1c00557.
Ghosh P, Mondal S, Hajra A
ACS Omega. 2019; 4(5):9049-9055.
PMID: 31459992
PMC: 6648136.
DOI: 10.1021/acsomega.9b01121.
YC-1 induces G/G phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells.
Lee M, Lin C, Lu C, Kuo S, Tsao J, Juan Y
Biomedicine (Taipei). 2017; 7(2):12.
PMID: 28612710
PMC: 5479426.
DOI: 10.1051/bmdcn/2017070205.
Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles.
Temple K, Duvernay M, Maeng J, Blobaum A, Stauffer S, Hamm H
Bioorg Med Chem Lett. 2016; 26(22):5481-5486.
PMID: 27777004
PMC: 5340293.
DOI: 10.1016/j.bmcl.2016.10.020.
Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.
Temple K, Duvernay M, Young S, Wen W, Wu W, Maeng J
J Med Chem. 2016; 59(16):7690-5.
PMID: 27482618
PMC: 5775816.
DOI: 10.1021/acs.jmedchem.6b00928.
Protease-activated receptor 4: from structure to function and back again.
French S, Hamilton J
Br J Pharmacol. 2016; 173(20):2952-65.
PMID: 26844674
PMC: 5341247.
DOI: 10.1111/bph.13455.
Synthesis and structure-activity relationship studies of novel 3,9-substituted α-carboline derivatives with high cytotoxic activity against colorectal cancer cells.
Lin Y, Chen Y, Tseng L, Lee Y, Morris-Natschke S, Kuo S
Eur J Med Chem. 2016; 110:98-114.
PMID: 26820553
PMC: 4754133.
DOI: 10.1016/j.ejmech.2016.01.004.
Crystal structure of 3-chloro-1-methyl-5-nitro-1H-indazole.
Kouakou A, Rakib E, Chigr M, Saadi M, El Ammari L
Acta Crystallogr E Crystallogr Commun. 2015; 71(Pt 11):o834-5.
PMID: 26594552
PMC: 4645045.
DOI: 10.1107/S2056989015018411.
Crystal structure of triethyl 2-(5-nitro-2H-indazol-2-yl)propane-1,2,3-tri-carboxyl-ate.
Boulhaoua M, Benchidmi M, Essassi E, Saadi M, El Ammari L
Acta Crystallogr E Crystallogr Commun. 2015; 71(Pt 10):o780-1.
PMID: 26594476
PMC: 4647391.
DOI: 10.1107/S2056989015017235.
Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354.
Wen W, Young S, Duvernay M, Schulte M, Nance K, Melancon B
Bioorg Med Chem Lett. 2014; 24(19):4708-4713.
PMID: 25176330
PMC: 5716344.
DOI: 10.1016/j.bmcl.2014.08.021.
6,6'-Di-nitro-1,1'-(ethane-1,2-di-yl)di(1H-indazole).
Kouakou A, Rakib E, El Malki A, Saadi M, El Ammari L
Acta Crystallogr Sect E Struct Rep Online. 2014; 70(Pt 4):o390.
PMID: 24826113
PMC: 3998527.
DOI: 10.1107/S1600536814004516.
2-Allyl-7-nitro-2H-indazole.
Kouakou A, Rakib E, Spinelli D, Saadi M, El Ammari L
Acta Crystallogr Sect E Struct Rep Online. 2014; 69(Pt 11):o1603-4.
PMID: 24454056
PMC: 3884280.
DOI: 10.1107/S1600536813026743.
Synthesis of indole derived protease-activated receptor 4 antagonists and characterization in human platelets.
Young S, Duvernay M, Schulte M, Lindsley C, Hamm H
PLoS One. 2013; 8(6):e65528.
PMID: 23776495
PMC: 3679140.
DOI: 10.1371/journal.pone.0065528.
A Robust Protocol for Pd(II)-catalyzed C-3 Arylation of () Indazoles and Pyrazoles: Total Synthesis of Nigellidine Hydrobromide.
Ye M, Edmunds A, Morris J, Sale D, Zhang Y, Yu J
Chem Sci. 2013; 4(6):2374-2379.
PMID: 23691269
PMC: 3656414.
DOI: 10.1039/C3SC50184A.
In silico prediction of SARS protease inhibitors by virtual high throughput screening.
Plewczynski D, Hoffmann M, von Grotthuss M, Ginalski K, Rychewski L
Chem Biol Drug Des. 2007; 69(4):269-79.
PMID: 17461975
PMC: 7188353.
DOI: 10.1111/j.1747-0285.2007.00475.x.
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.
Evgenov O, Pacher P, Schmidt P, Hasko G, Schmidt H, Stasch J
Nat Rev Drug Discov. 2006; 5(9):755-68.
PMID: 16955067
PMC: 2225477.
DOI: 10.1038/nrd2038.